drugset / Trial / NCT04835623
CEQUA for Sjogren's Syndrome Dry Eye
Phase 4
Completed
50 enrolled
Center for Ophthalmic and Vision Research, LLC
Sun Pharmaceutical Industries, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.
Timeline
- Start
- 2021-06-21
- Primary completion
- 2024-03-21
- Completion
- 2024-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 0.09 % | — |